- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02816736
EntrestoTM (LCZ696) In Advanced Heart Failure (LIFE Study) (HFN-LIFE)
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Patients with advanced heart failure with reduced ejection fraction (HFrEF) have extremely high morbidity and mortality with 1 year outcomes of death and hospitalization of approximately 50%. For the most advanced heart failure patients, the evidence base for medical treatment is limited with consensus guidelines recommending consideration for either cardiac transplant or ventricular assist device, or palliative care.
The PARADIGM-HF trial showed that LCZ696, which consists of the neprilysin inhibitor sacubitril and the ARB valsartan, improved morbidity and mortality in patients with chronic HFrEF in comparison to enalapril. However, limited experience with advanced heart failure patients was gained from patients enrolled in the trial. Because the information on the effects of sacubitril/valsartan in patients with NYHA class IV heart failure is limited, the updated 2016 ACC/AHA/HFSA guidelines for the treatment of heart failure do not yet endorse the use of sacubitril/valsartan in patients with NYHA class IV heart failure. Accordingly, experience is needed on the use of, and outcomes with LCZ696 in patients unable to tolerate target doses of angiotensin-converting enzyme inhibitor (ACEI)/ angiotensin receptor blocker (ARB).
This study will be a randomized, double-blinded trial of advanced heart failure subjects with 1:1 randomization to either LCZ696 (sacubitril and valsartan) or valsartan. Study drug will be administered in a double-dummy fashion, in which subjects take active (LCZ696 or valsartan) and placebo. Approximately 400 subjects will be randomized into the study.
Subjects will have an initial screening evaluation, including baseline laboratory tests as well as an assessment of left ventricular (LV) ejection fraction, at which time preliminary subject eligibility will be determined. The LV ejection fraction may have been obtained within the prior 12 months by 2-D echocardiogram, LV angiogram or radionuclide scintigraphy. Willing subjects meeting entry criteria will be consented. Those who meet all entry criteria and are interested in study participation will be enrolled.
Enrolled subjects will complete baseline assessments and undergo a run-in period of 3-7 days with LCZ696 50 mg (equivalent to Entresto™ 24/26 mg) po BID (taken by mouth twice a day) prior to randomization. For subjects taking an ACEI, the ACEI will be withheld for ≥ 36 hours prior to first dose of LCZ696.
Subjects who tolerate the run-in period with LCZ696 will be randomized 1:1 to LCZ696 or valsartan.
Study treatment will be titrated to the target dose of 200 mg LCZ696 (equivalent to Entresto™ 97/103 mg) as two 100 mg LCZ696 and 2 placebo tablets po BID or valsartan 160 mg (two 80 mg valsartan and 2 placebo tablets) po BID.*
Randomized subjects will receive the first dose of study drug as follows:
- For subjects not previously taking ACEI or ARB, previously taking ACEI or ARB at a low dose*, or subjects who have an eGFR < 30 mL/min/1.73m², the starting dose of valsartan will be 40 mg po BID and the starting dose of LCZ696 will be 50 mg po BID.
- For subjects taking an ARB at greater than low dose†, the starting dose of valsartan will be 80 mg po BID and the starting dose of LCZ696 will be 100 mg po BID.*
For subjects taking an ACEI at greater than low dose†, the ACEI will be withheld for ≥ 36 hours prior to randomization. The starting dose of valsartan will be 80 mg po BID and the starting dose of LCZ696 will be 100 mg po BID.*
- At Investigator discretion, study drug may be started at the low dose (LCZ696/placebo 50 mg po BID or valsartan/placebo 40 mg po BID) if there are any concerns regarding tolerability at the 100 mg / 80 mg dose.)
Per package insert, the valsartan compounded in Entresto™ is more bioavailable than the valsartan in other marketed formulations. The dose equivalence for valsartan compounded in Entresto™ compared to valsartan prepared alone (Entresto™ dose = marketed valsartan dose) is as follows: 26 mg=40 mg, 51 mg=80 mg, 103 mg=160 mg.
† Low dose is defined as 24 hour dose of ≤ 10 mg lisinopril, ≤ 5 mg ramipril, ≤ 50 mg losartan, ≤ 10 mg olmesartan, or other dose equivalent.
Dose adjustments will be performed every 2 weeks by doubling the dose of LCZ696 or valsartan up to the target maximum dose. The doses of LCZ696 are 50 mg (one 50 mg active and 1 placebo tablet), 100 mg (one 100 mg active and 1 placebo tablet) and 200 mg (two 100 mg active and 2 placebo tablets). These doses are equivalent to 24/26 mg, 49/51 mg, and 97/103 mg commercial Entresto™, respectively. The doses of valsartan are 40mg (one 40 mg active and 1 placebo tablet), 80 mg (one 80 mg active and 1 placebo tablet), and 160 mg (two 80 mg active and 2 placebo tablets). The criteria for doubling the dose will be based on systolic blood pressure (a SBP > 90 mmHg is required for up titration), changes in renal function (maximum serum creatinine of 2.0 mg/dL), and the absence of symptoms of hypotension. For those not tolerating the current dose of study drug, the dose will be down-titrated to the previous tolerated dose. Subjects will return to clinic for follow-up visits at 2, 4, 8, 12, and 24 weeks after randomization.
Assessments at the follow-up visits include some or all of the following: interim medical history, review of medications, physical examination with the New York Heart Association (NYHA) class assessment, Kansas City Cardiomyopathy Questionnaire (KCCQ) quality of life questionnaire, local laboratory testing (creatinine, Blood Urea Nitrogen (BUN), electrolytes), Core laboratory testing (Cystatin C, BNP, NT-proBNP), adherence and tolerance assessment, and adverse event monitoring.
Follow-up phone calls will be made at 10, 16, and 20, weeks after randomization to assess dosing compliance, record the occurrence of applicable adverse events and events of interest, and remind the subject of the date and time of their next in-person visit.
A final phone visit is conducted approximately 2 weeks after study visit 10 (26 weeks after randomization) to assess clinical stability and any applicable adverse events.
During the consent process, subjects will be asked if interested in donating samples and data for research purposes via a biorepository and/or genetic study. Based on site and IRB preference, this optional part of the study may be incorporated into the main consent or may be a separate consent and Institutional Review Board (IRB) application.
Study Type
Enrollment (Actual)
Phase
- Phase 4
Contacts and Locations
Study Locations
-
-
California
-
Beverly Hills, California, United States, 90211
- Cedars-Sinai Heart Institute
-
Sacramento, California, United States, 95816
- Sutter Health Mills-Peninsula Health Services
-
San Diego, California, United States, 92123
- San Diego Cardiac Center
-
-
District of Columbia
-
Washington, District of Columbia, United States, 20010
- MedStar Washington Hospital Center
-
-
Georgia
-
Atlanta, Georgia, United States, 30322
- Emory University School of Medicine
-
Atlanta, Georgia, United States, 30309
- Piedmont Heart Institute
-
-
Illinois
-
Oak Lawn, Illinois, United States, 60453
- Advocate Christ Medical Center
-
-
Indiana
-
Indianapolis, Indiana, United States, 46260
- St. Vincent Medical Group
-
-
Louisiana
-
New Orleans, Louisiana, United States, 70121
- Ochsner Clinic Foundation
-
-
Maryland
-
Baltimore, Maryland, United States, 21287
- Johns Hopkins Hospital
-
-
Massachusetts
-
Boston, Massachusetts, United States, 02115
- Brigham and Women's Hospital
-
Boston, Massachusetts, United States, 02114
- Massachusetts General Hospital
-
Boston, Massachusetts, United States, 02111
- Tufts Medical Center
-
-
Michigan
-
Ann Arbor, Michigan, United States, 48109
- University of Michigan Health System
-
-
Minnesota
-
Rochester, Minnesota, United States, 55905
- Mayo Clinic
-
-
Missouri
-
Saint Louis, Missouri, United States, 63110
- Washington University
-
Saint Louis, Missouri, United States, 63117
- Saint Louis University Hospital
-
-
New York
-
New York, New York, United States, 10029
- Mount Sinai Hospital
-
Stony Brook, New York, United States, 11794
- Stony Brook University Medical Center
-
-
North Carolina
-
Charlotte, North Carolina, United States, 28203
- Charlotte-Mecklenburg Hospital Authority
-
Durham, North Carolina, United States, 27705
- Duke University Medical Center
-
-
Ohio
-
Cincinnati, Ohio, United States, 45219
- The Christ Hospital
-
Cleveland, Ohio, United States, 44195
- Cleveland Clinic
-
Cleveland, Ohio, United States, 44109
- Metro Health System
-
Cleveland, Ohio, United States, 44106
- Case Western Medical Center
-
Columbus, Ohio, United States, 43210
- The Ohio State University Medical Center
-
-
Oklahoma
-
Oklahoma City, Oklahoma, United States, 73112
- Integris Baptist Medical Center
-
-
Oregon
-
Portland, Oregon, United States, 97239
- Oregon Health and Science University
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, United States, 19104
- University of Pennsylvania
-
Philadelphia, Pennsylvania, United States, 19107
- Thomas Jefferson University Hospital
-
Pittsburgh, Pennsylvania, United States, 15212
- Allegheny General Hospital
-
Wilkes-Barre, Pennsylvania, United States, 18711
- Geisinger Medical Center
-
-
Tennessee
-
Nashville, Tennessee, United States, 37232
- Vanderbilt University Medical Center
-
-
Texas
-
Houston, Texas, United States, 77030
- Houston Methodist Research Institute
-
-
Utah
-
Salt Lake City, Utah, United States, 84132
- University of Utah School of Medicine
-
-
Virginia
-
Falls Church, Virginia, United States, 22042
- Inova Heart and Vascular Insititute
-
Norfolk, Virginia, United States, 23507
- Sentara Norfolk General Hospital
-
-
Washington
-
Seattle, Washington, United States, 98195
- University of Washington Medical Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
Advanced HFrEF defined as including ALL
- LVEF≤ 35% documented during the preceding 12 months
- NYHA class IV symptomatology, defined as chronic dyspnea or fatigue at rest or on minimal exertion in the previous 3 months, or patients who require chronic inotropic therapy
- Minimum of 3 months GDMT for HF and/or intolerant to therapy
- Systolic blood pressure ≥ 90 mmHg
- Serum NT-proBNP ≥ 800 pg/mL OR BNP ≥ 250 pg/mL (most recent - less than 3 months old)
Any one or more of the following objective findings of advanced HF including:
- Current inotropic therapy or use of inotropes in the past 6 months
- ≥ 1 hospitalization for heart failure in the past 6 months (not including the index hospitalization for inpatient participants)
- LVEF ≤ 25% (within the past 12 months)
- Peak VO2 < 55% predicted or peak VO2 ≤ 16 for men or ≤ 14 for women (Respiratory Exchange Ratio (RER) ≥ 1.05) (within the past 12 months)
- 6 min walk test distance < 300 m (within the past 3 months)
- Age ≥18 years and ≤ 85 years
- Signed Informed Consent form
Exclusion Criteria:
- Currently taking Entresto™
- History of hypersensitivity or intolerance (unmodifiable) to Entresto™, an ACEI or ARB as well as known or suspected contraindications (including hereditary angioedema) to the study drugs.
- Estimated glomerular filtration rate (eGFR) < 20 mL/min/1.73 m2 at baseline
- Co-morbid conditions that may interfere with completing the study protocol (e.g. recent history of drug or alcohol abuse) or cause death within 1 year
- Symptomatic hypotension at randomization or systolic blood pressure < 90 mmHg
- Serum potassium > 5.5 mmol/L
- Severe liver dysfunction (Childs-Pugh Class C)
- Acute coronary syndrome within 4 weeks as defined by electrocardiographic (ECG) changes and biomarkers of myocardial necrosis (e.g. troponin) in an appropriate clinical setting (chest discomfort or anginal equivalent)
- Planned or recent (≤ 4 weeks) PCI, coronary artery bypass grafting, or biventricular pacing
- Currently hospitalized and listed status 1A, 1B or 1-4 for heart transplant
- Current or scheduled for LVAD implantation within 30 days of study enrollment
- Active infection (current use of oral or IV antimicrobial agents)
- Primary hypertrophic or infiltrative cardiomyopathy, acute myocarditis, constrictive pericarditis or tamponade
- Complex congenital heart disease
- Concomitant use of aliskiren in patients with diabetes or renal impairment (eGFR <60 mL/min/1.73 m²)
- Known pregnancy or anticipated pregnancy within the next 6 months or breastfeeding mothers
- Enrollment in any other investigational clinical trial within 30 days prior to screening
- Inability to comply with study procedures
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: LCZ696 (Entresto) + placebo
LCZ696 50 mg, 100 mg, or 200 mg orally twice daily for 24 weeks, plus valsartan placebo (to match 40 mg, 80 mg, or 160 mg) orally twice daily for 24 weeks
|
Subjects previously taking no or low-dose ACEI or ARB, or who have an eGFR < 30 mL/min/1.73m²: starting dose of LCZ696 = 50 mg po BID. Subjects taking an ARB at greater than low dose: starting dose of LCZ696 = 100 mg po BID. Subjects taking an ACEI at greater than low dose: starting dose of LCZ696 = 100 mg po BID. * At Investigator discretion, study drug may be started at the low dose if there are any concerns regarding tolerability. Dose adjustments will be performed every 2 weeks by doubling the dose of LCZ696 up to the target max dose of 200 mg po BID as tolerated. The doses of LCZ696 are 50mg (one low-dose (50mg) tablet), 100mg (one high-dose (100mg) tablet), and 200mg (two high-dose (100mg) tablets.) These doses are equivalent to 24/26 mg, 49/51 mg, and 97/103 mg commercial Entresto™, respectively.
Other Names:
Valsartan placebo tablets will be supplied to match the low-dose (40mg) and high-dose (80mg) active valsartan tablets.
Dosing for valsartan placebo will mirror dosing for active LCZ696 (the same number of low or high-dose tablets will be given.)
|
Active Comparator: valsartan + placebo
valsartan 40 mg, 80 mg, or 160 mg orally twice daily for 24 weeks, plus LCZ696 placebo (to match 50 mg, 100 mg, or 200 mg) orally twice daily for 24 weeks
|
Subjects previously taking no or low-dose ACEI or ARB, or who have an eGFR < 30 mL/min/1.73m²: the starting dose of valsartan = 40 mg po BID. Subjects taking an ARB at greater than low dose: starting dose of valsartan = 80 mg po BID. Subjects taking an ACEI at greater than low dose: starting dose of valsartan = 80 mg po BID. * At Investigator discretion, study drug may be started at the low dose if there are any concerns regarding tolerability. Dose adjustments will be performed every 2 weeks by doubling the dose of valsartan up to the target maximum dose of 160 mg po BID, as tolerated. The doses of valsartan are 40mg (one low-dose (40mg) tablet), 80mg (one high-dose (80mg) tablet), and 160mg (two high-dose (80mg) tablets).
Other Names:
LCZ696 placebo tablets will be supplied to match the low-dose (50mg) and high-dose (100mg) active LCZ696 tablets.
Dosing for LCZ696 placebo will mirror dosing for active valsartan (the same number of low or high-dose tablets will be given.)
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in NT-proBNP
Time Frame: Baseline, 2, 4, 8, 12, and 24 weeks
|
The proportional change from baseline in the AUC for NT-proBNP levels measured at 2, 4, 8, 12, and 24 weeks.
AUC was normalized for time and divided by the baseline value of NTproBNP so it has no unitshas no units.
With the log-scale, the value of 0 indicates, on average, no change in NTproBNP from baseline.
A value > 0 indicates an increase in log NT Pro BNP relative to baseline and a value < 0 indicates a decrease in log NT Pro BNP relative to baseline.
|
Baseline, 2, 4, 8, 12, and 24 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Composite Endpoint of the Effects of LCZ696 (Number of Days)
Time Frame: Randomization through 24 weeks
|
Composite endpoint of effects of LCZ696 compared to valsartan over 24 weeks will be compared based upon the number of days subjects are
|
Randomization through 24 weeks
|
Tolerability - Target Dose
Time Frame: Randomization through 24 weeks
|
Tolerability as measured by number of subjects achieving a target dose of 0% (stopped study drug early or was never started on study drug), 25%, 50% or 100% of valsartan or LCZ696 (based on last dose of study drug taken prior to end of study)
|
Randomization through 24 weeks
|
Tolerability - Hypotension
Time Frame: Randomization through 24 weeks
|
Tolerability as measured by number of subjects developing hypotension (SBP ≤ 85 mmHg) with symptoms
|
Randomization through 24 weeks
|
Tolerability - Renal Function
Time Frame: Randomization through 24 weeks
|
Tolerability as measured by number of subjects developing worsening renal function (eGFR < 20 ml/min/1.73
m²)
|
Randomization through 24 weeks
|
Tolerability - Hyperkalemia
Time Frame: Randomization through 24 weeks
|
Tolerability as measured by number of subjects developing moderate (>/= 5.5 mmol/L-5.9
mmol/L) or severe (>/= 6 mmol/L) hyperkalemia
|
Randomization through 24 weeks
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Time to Death
Time Frame: Randomization through 24 weeks
|
Time to death through 24 weeks
|
Randomization through 24 weeks
|
Time to First Heart Failure (HF) Hospitalization
Time Frame: Randomization through 24 weeks
|
Time to first HF hospitalization through 24 weeks
|
Randomization through 24 weeks
|
Time to Death and First Heart Failure (HF) Hospitalization
Time Frame: Randomization through 24 weeks
|
Time to death and first HF hospitalization through 24 weeks
|
Randomization through 24 weeks
|
Total Number of Heart Failure (HF) Hospitalizations
Time Frame: Randomization through 24 weeks
|
Total number of HF hospitalization admissions through 24 weeks
|
Randomization through 24 weeks
|
Inotropic Therapy
Time Frame: Randomization through 24 weeks
|
Number of subjects on continuous inotropic therapy >/= 7 days after discharge from the index hospitalization through 24 weeks
|
Randomization through 24 weeks
|
Number of Subjects Listed for Transplant (Status 1A, 1B or 1-4), Transplanted or Implanted With an LVAD
Time Frame: Randomization through 24 weeks
|
Number of subjects listed for transplant (status 1A, 1B or 1-4), transplanted or implanted with an LVAD through 24 weeks.
|
Randomization through 24 weeks
|
Change in eGFR and Cystatin C Levels
Time Frame: Randomization through 24 weeks
|
Change in eGFR and cystatin C levels compared to baseline.
Renal function will be assessed at baseline, 4, 8, 12, and 24 weeks
|
Randomization through 24 weeks
|
Unanticipated IV Diuretic Use
Time Frame: Randomization through 24 weeks
|
Number of subjects with unanticipated use of IV diuretics (outpatient, ER or inpatient) through 24 weeks.
|
Randomization through 24 weeks
|
Change in AUC in the Kansas City Cardiomyopathy Questionnaire (KCCQ)
Time Frame: Randomization through 24 weeks
|
Difference in AUC of the KCCQ at 4, 12 and 24 weeks
|
Randomization through 24 weeks
|
Change in AUC for the Ratio of NT-proBNP/BNP
Time Frame: Randomization through 24 weeks
|
The change in AUC for the ratio of NT-proBNP/BNP from baseline to weeks 2, 4, 8, 12 and 24 weeks
|
Randomization through 24 weeks
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Kevin Anstrom, Duke Health
Publications and helpful links
General Publications
- Vader JM, Givertz MM, Starling RC, McNulty SE, Anstrom KJ, Desvigne-Nickens P, Hernandez AF, Braunwald E, Mann DL; LIFE Investigators. Tolerability of Sacubitril/Valsartan in Patients With Advanced Heart Failure: Analysis of the LIFE Trial Run-In. JACC Heart Fail. 2022 Jul;10(7):449-456. doi: 10.1016/j.jchf.2022.04.013.
- Mann DL, Givertz MM, Vader JM, Starling RC, Shah P, McNulty SE, Anstrom KJ, Margulies KB, Kiernan MS, Mahr C, Gupta D, Redfield MM, Lala A, Lewis GD, DeVore AD, Desvigne-Nickens P, Hernandez AF, Braunwald E; LIFE Investigators. Effect of Treatment With Sacubitril/Valsartan in Patients With Advanced Heart Failure and Reduced Ejection Fraction: A Randomized Clinical Trial. JAMA Cardiol. 2022 Jan 1;7(1):17-25. doi: 10.1001/jamacardio.2021.4567.
- Mann DL, Greene SJ, Givertz MM, Vader JM, Starling RC, Ambrosy AP, Shah P, McNulty SE, Mahr C, Gupta D, Redfield MM, Lala A, Lewis GD, Mohammed SF, Gilotra NA, DeVore AD, Gorodeski EZ, Desvigne-Nickens P, Hernandez AF, Braunwald E; LIFE Investigators. Sacubitril/Valsartan in Advanced Heart Failure With Reduced Ejection Fraction: Rationale and Design of the LIFE Trial. JACC Heart Fail. 2020 Oct;8(10):789-799. doi: 10.1016/j.jchf.2020.05.005. Epub 2020 Jun 10. Erratum In: JACC Heart Fail. 2020 Dec;8(12):1059.
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- Pro00071722
- 5U01HL084904 (U.S. NIH Grant/Contract)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Heart Failure
-
Tufts Medical CenterMetro West Medical CenterCompletedCongestive Heart Failure | Diastolic Heart Failure | Systolic Heart FailureUnited States
-
Abbott Medical DevicesCompletedHeart Failure | Heart Failure, Diastolic | Heart Failure, Systolic | Heart Failure NYHA Class II | Heart Failure NYHA Class III | Heart Failure With Reduced Ejection Fraction | Heart Failure NYHA Class IV | Heart Failure With Normal Ejection Fraction | Heart Failure; With Decompensation | Heart Failure...United States, Canada
-
Manipal UniversityUnknownHeart Failure | Decompensated Heart Failure | Acute Heart Failure | Diastolic Heart Failure | Systolic Heart FailureIndia
-
VA Eastern Colorado Health Care SystemNational Institute on Aging (NIA)CompletedHeart Failure | Heart Failure, Diastolic | Heart Failure, Systolic | Heart Failure With Reduced Ejection Fraction | Heart Failure With Preserved Ejection Fraction | Heart Failure; With Decompensation | Heart Failure,Congestive | Heart Failure AcuteUnited States
-
University Hospital, MontpellierCompletedHeart Failure | Diastolic Heart Failure | Systolic Heart Failure Stage CFrance
-
Wake Forest UniversityCompletedHeart Failure, Congestive | Heart Failure With Preserved Ejection Fraction
-
Lancaster General HospitalLouise von Hess Medical Research InstituteEnrolling by invitationDiastolic Heart FailureUnited States
-
Wake Forest UniversityNational Institute on Aging (NIA)CompletedHeart Failure, Congestive | Diastolic Heart FailureUnited States
-
Giresun UniversityIstanbul University - Cerrahpasa (IUC)RecruitingHeart Failure | Diastolic Heart Failure | Systolic Heart FailureTurkey
-
US Department of Veterans AffairsCompleted
Clinical Trials on LCZ696
-
Novartis PharmaceuticalsCompleted
-
Novartis PharmaceuticalsCompletedHeart Failure and Reduced Ejection FractionUnited States
-
Novartis PharmaceuticalsCompletedHypertensionUnited States, Spain, Philippines, Guatemala, Russian Federation, Argentina, Puerto Rico
-
Novartis PharmaceuticalsCompletedChronic Heart Failure With Reduced Ejection FractionBelgium, Estonia, Denmark, Greece, United Kingdom, Germany, Latvia, Lithuania, Spain, Netherlands, Bulgaria, Finland, Poland, Czechia, Iceland, Sweden, France, Ireland, Norway
-
Novartis PharmaceuticalsCompletedChronic Heart Failure (CHF)Spain, Croatia, Taiwan, Germany, Italy, United States, Australia, Netherlands, Switzerland, Belgium, United Kingdom, Bulgaria, Lithuania, Russian Federation, France, Argentina, Korea, Republic of, Poland, Canada, Turkey
-
University Hospital, MontpellierCompletedChronic Heart Failure | Sleep Apnea SyndromeFrance
-
Novartis PharmaceuticalsCompletedEssential HypertensionChina, Korea, Republic of, Taiwan, Hong Kong, Thailand, Philippines, Singapore
-
Novartis PharmaceuticalsCompletedChronic Heart Failure With Reduced Ejection FractionGermany
-
Novartis PharmaceuticalsCompletedHeart Failure | Erectile Dysfunction | Heart Failure, SystolicGermany
-
Novartis PharmaceuticalsCompletedHeart Failure With Reduced Ejection Fraction (HF-rEF)Japan